Celldex Therapeutics (NASDAQ:CLDX) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $21.24 and traded as high as $22.37. Celldex Therapeutics shares last traded at $21.98, with a volume of 978,039 shares traded.

Analysts Set New Price Targets

Several analysts recently commented on CLDX shares. UBS Group decreased their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Celldex Therapeutics in a report on Friday, June 13th. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 price objective on the stock. Morgan Stanley cut their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Finally, The Goldman Sachs Group cut their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $50.11.

Celldex Therapeutics Trading Down 0.6%

The company has a market cap of $1.46 billion, a P/E ratio of -8.14 and a beta of 1.13. The firm's fifty day moving average price is $20.37 and its 200-day moving average price is $21.18.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative net margin of 2,366.07% and a negative return on equity of 23.46%. As a group, research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Several large investors have recently added to or reduced their stakes in CLDX. Charles Schwab Investment Management Inc. grew its stake in Celldex Therapeutics by 1.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company's stock worth $13,755,000 after buying an additional 5,474 shares during the last quarter. E Fund Management Co. Ltd. bought a new stake in Celldex Therapeutics during the fourth quarter worth about $273,000. AlphaQuest LLC grew its stake in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 878 shares during the last quarter. Finally, Swiss National Bank lifted its position in shares of Celldex Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock worth $2,964,000 after purchasing an additional 1,400 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.